Close

BioLineRx (BLRX) Submits Regulatory Filings Needed to Commence BL-8040 Combo Phase 2a in Pancreatic Cancer

June 28, 2016 7:11 AM EDT Send to a Friend
BioLineRx Ltd. (Nasdaq: BLRX) announced the filing of regulatory submissions required to commence a Phase 2a trial for BL-8040 in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login